Dario Amodei: recommendation

Transcript context

…And there would be the inventors of a CRISPR type technology. They would be the inventors of a CRISPR type technology. And then I think, as I say in the essay, we’ll want to turn, probably turning loose is the wrong term, but we’ll want to harness the AI systems to improve the clinical trial system as well. There’s some amount of this that’s regulatory, that’s a matter of societal decisions and that’ll be harder. But can we get better at predicting the results of clinical trials? Can we get better at statistical design so that clinical trials that used to require 5,000 people and therefore needed $100 million in a year to enroll them, now they need 500 people in two months to enroll them? That’s where we should start. And can we increase the success rate of clinical trials by doing things in animal trials that we used to do in clinical trials and doing things in simulations that we used to do in animal trials? Again, we won’t be able to simulate at all. AI is not God, but can we shift the curve substantially and radically? So I don’t know, that would be my picture. Doing in vitro and doing it. I mean you’re still slowed down. It still takes time, but you can do it much, much faster.…

Stored transcript either side of the excerpt. The highlighted words are the published quote; the surrounding text is unedited source, never generated.